# Teleflex account plan

> Teleflex makes single-use medical devices for critical care and surgery; FY2025 continuing revenue $1,992.7 million, 2026 guide $2,256-2,276 million.

## At a glance

Teleflex Incorporated, based in Wayne, PA, designs, manufactures and supplies single-use medical devices for critical care and surgical procedures, sold to hospitals through a direct sales force and distributors; major plants are in the Czech Republic, Malaysia, Mexico and the U.S. FY2025 net revenues from continuing operations were $1,992.7 million (+17.2%), boosted by the acquired BIOTRONIK Vascular Intervention business, while the group posted a net loss of $905.6 million driven by impairments on businesses being sold. After selling OEM in August 2026 and with Acute Care and Interventional Urology under sale, it now runs three global units: Vascular, Interventional and Surgical. It employed approximately 15,500 people at December 31, 2025; Jason Weidman has been President and CEO since June 8, 2026.

## Business units

- **Vascular** (about 46% of FY2025 continuing revenue ($917.7 million)): Arrow catheters and tip positioning systems, EZ-IO and Arrow FAST1 intraosseous access, and QuikClot hemostatic products. Q3 2026 revenue was $243.5 million (+4.7%) with operating profit up 17.3%; EZPLAZ freeze-dried plasma was approved by the FDA in July 2026.
- **Interventional** (about 33% of FY2025 continuing revenue ($647.8 million)): Coronary and peripheral catheters, structural heart support, the MANTA closure device and, since June 30, 2025, BIOTRONIK VI stents and drug-coated balloons. Q3 2026 revenue was $210.3 million (-2.6%) as the VI integration lagged; Jason Fontana leads the unit.
- **Surgical** (about 21% of FY2025 continuing revenue ($418.2 million)): Ligation clips, laparoscopic closure, a powered bariatric stapler and ENT and cardio-thoracic instruments (Weck, Pleur-Evac, Titan SGS). Q3 2026 revenue was $114.0 million (+4.2%).
- **Acute Care, Interventional Urology and OEM (divested or being divested)**: FY2025 revenue of $1,304.3 million, reported as discontinued operations. OEM was sold to Montagu and Kohlberg on August 3, 2026; Acute Care and Interventional Urology (UroLift, Barrigel) are being sold to Intersurgical for about $530 million, possibly closing in 2027.

## Strategic priorities

- **Complete the transformation**: Close the Acute Care and Interventional Urology sale, targeted by end of 2026 but possibly 2027 after an FTC second request, and finish integrating Interventional.
- **Simpler operating model**: Move from a geographic matrix to three global business units, each owning its strategy, resources and results.
- **Raise the growth profile through innovation**: R&D raised to close to 8% of revenue, with Freesolve resorbable magnesium scaffold (BIOMAG data due late 2027) and EZPLAZ, a U.S. opportunity of at least $200 million.
- **Return capital and cut debt**: Plan of $1 billion of buybacks and $800 million of debt reduction from divestiture proceeds; net leverage about 1.4x in Q3 2026.
- **Margin step-up**: Adjusted operating margin about 20.0% in 2026, approximating 23% in the first year after the Acute Care and IU close, with about $50 million of annual restructuring savings.

## Latest results

In Q3 2026 (quarter ended September 30, 2026) revenue from continuing operations was $567.8 million, up 0.2% reported and 3.0% on a pro forma adjusted constant currency basis. Gross margin rose to 65.0% from 51.5%, helped by the end of VI inventory step-up and a $25.3 million IEEPA tariff refund, and adjusted diluted EPS was $2.63 (vs $1.89). Net income was $927.4 million including the gain on the OEM sale. Teleflex kept its 2026 pro forma constant currency growth guidance at 3.5%-4.5%, cut GAAP revenue guidance to $2,256-2,276 million on FX and raised adjusted EPS guidance to $7.50-$7.75.

## Investments and deals

- **BIOTRONIK Vascular Intervention acquisition**: Acquired June 30, 2025 for a net €704.3 million ($825.2 million), adding $202.4 million of 2025 revenue.
- **OEM divestiture**: Closed August 3, 2026: net cash proceeds of $1.5 billion ($1.25 billion after tax).
- **Share repurchases**: 4.6 million shares bought for $600.0 million in 2026 to the filing date, with $400.0 million left on the $1 billion authorization.
- **Restructuring plans**: VI integration plan targeting $24-30 million of annual savings by end of 2028, and the Strategic Divestitures plan targeting $48-52 million by mid-2028.
- **New ERP**: Ongoing development of a new ERP solution raised IT costs.

## Challenges and risks

- **Slow VI integration**: Order-to-cash, distributor and sales force transitions held Interventional back; open territories are down 63% from peak and new reps need about 6 months to become productive.
- **Tariffs**: Tariff costs of a little over $30 million in 2026, with similar levels expected in 2027.
- **Divestiture timing**: The Acute Care and IU sale faces an FTC second request and may slip into 2027, with stranded costs to remove.
- **GLP-1 impact on bariatric surgery**: Reduced bariatric procedures led to a $100.0 million impairment on the Titan SGS asset group in 2025.
- **China procurement and sterilization rules**: China volume-based procurement cuts prices, and EPA ethylene oxide emission standards affect contract sterilizers Teleflex depends on.

## What leadership says

> "a meaningful step-up in adjusted earnings per share" — Jason Weidman, President and CEO, On 2027, Q3 2026 earnings call, November 5, 2026

> "this is absolutely not a product issue" — Jason Weidman, President and CEO, On the Interventional integration, Q2 2026 earnings call, August 6, 2026

> "a more focused, agile and growth-oriented Teleflex" — Jason Weidman, President and CEO, Q3 2026 earnings call, November 5, 2026

> "we're confident this transaction will be completed." — Jason Weidman, President and CEO, On the Acute Care and IU sale, Q3 2026 earnings call, November 5, 2026


## Where a supplier can help

- **Order-to-cash and distributor transitions**: The VI integration challenge sits in ordering, distributor and consignment processes; supply chain, ERP and order management partners can help close it.
- **Sales force onboarding**: Refilling territories with reps who need about 6 months to ramp creates demand for sales training, enablement and territory planning tools.
- **Stranded cost removal**: The Strategic Divestitures restructuring plan targets $48-52 million of savings, favouring shared services, IT and process simplification vendors.
- **Clinical trial and R&D support**: Higher R&D spend and the BIOMAG III U.S. pivotal trial call for CROs, clinical data and regulatory services.
- **Tariff and supply chain optimisation**: Tariff mitigation through supply chain changes and more USMCA-compliant products needs sourcing, trade compliance and logistics expertise.

_Tamtam's reading of the priorities and challenges above, not the company's own words._

## Key documents

### [Teleflex Incorporated Annual Report on Form 10-K for fiscal year 2025](https://www.sec.gov/Archives/edgar/data/96943/000009694326000019/tfx-20251231.htm)

Annual report · 2026-02-27

- Teleflex is a Wayne, PA medical technology company designing, manufacturing and supplying single-use medical devices for critical care and surgical procedures, sold to hospitals and healthcare providers through its direct sales force and distributors; major plants are in the Czech Republic, Malaysia, Mexico and the U.S.
- FY2025 net revenues from continuing operations were $1,992.7 million, up 17.2%, mainly from $202.4 million contributed by the acquired BIOTRONIK Vascular Intervention (VI) business; gross margin fell to 56.2% from 61.0%.
- In February 2025 Teleflex announced a strategic transformation; on December 9, 2025 it agreed to sell Acute Care and Interventional Urology to Intersurgical Ltd ($530 million) and OEM to Montagu and Kohlberg (about $1.5 billion), $2.0 billion in cash in total, now reported as discontinued operations (FY2025 revenue $1,304.3 million).
- Continuing portfolio by product category in FY2025: Vascular $917.7 million (Arrow catheters, EZ-IO, QuikClot), Interventional $647.8 million (GuideLiner, MANTA, VI stents and drug-coated balloons), Surgical $418.2 million (Weck, Pleur-Evac, Titan SGS).
- Net loss of $905.6 million in FY2025, driven by a $964.2 million loss from discontinued operations (goodwill impairments and a $747.1 million valuation allowance on the disposal group); a $100.0 million Titan SGS impairment hit continuing operations, linked to GLP-1 drugs reducing bariatric surgery.
- Expected net after-tax proceeds of about $1.8 billion go mainly to share repurchases and debt paydown; the Board authorized a $1.0 billion buyback on December 9, 2025.
- Leadership change: CEO and chairman Liam J. Kelly left on January 8, 2026; Stuart A. Randle became Interim President and CEO, Stephen K. Klasko independent chair; John R. Deren is CFO.
- Restructuring: the VI Business integration plan targets $24-30 million annual savings and the Strategic Divestitures restructuring plan $48-52 million, both running to 2028.
- Key risks: execution of the transformation and stranded costs, U.S. tariffs (EU imports and non-USMCA-compliant Mexican products), China volume-based procurement, ethylene oxide sterilization rules, U.S. distributor destocking and the CEO transition.

### [Teleflex Incorporated Quarterly Report on Form 10-Q for the quarter ended September 30, 2026](https://www.sec.gov/Archives/edgar/data/96943/000009694326000109/tfx-20260930.htm)

Interim report · 2026-11-05

- Q3 2026 (quarter ended September 30, 2026) net revenues from continuing operations were $567.8 million (+0.2%); nine-month revenues $1,686.4 million (+18.4%), helped by $198.1 million from the acquired VI business.
- From Q3 2026 Teleflex reports three global product segments instead of geographic ones: Vascular ($243.5 million, +4.7%), Interventional ($210.3 million, -2.6%) and Surgical ($114.0 million, +4.2%).
- Q3 gross margin rose to 65.0% from 51.5%, helped by non-recurrence of VI inventory step-up and a $25.3 million IEEPA tariff refund, partly offset by quality remediation costs.
- The OEM sale to Montagu and Kohlberg closed on August 3, 2026: net cash proceeds $1.5 billion ($1.3 billion after tax) and a $1.0 billion pre-tax gain; Q3 net income was $927.4 million.
- The Acute Care and IU sale to Intersurgical (gross proceeds about $530 million) is expected by end of 2026 but may slip into 2027.
- Proceeds repaid the $700 million term loan A-2 and $490.0 million of the revolver; 4.6 million shares repurchased for $600.0 million in 2026 to the filing date, $400.0 million left on the $1 billion authorization.
- Leadership: Jason Weidman became President and CEO on June 8, 2026; Andrew A. Krakauer is Chairman; Sean M. Salmon joined the Board on September 8, 2026.
- Strategic Divestitures restructuring plan now $34-40 million of charges for $48-52 million of annual pre-tax savings by mid-2028.

### [Teleflex Reports Third Quarter Financial Results and Full Year 2026 Outlook](https://www.sec.gov/Archives/edgar/data/96943/000009694326000107/ex991to11-5x2026req32026ea.htm)

Interim report · 2026-11-05

- Teleflex's Q3 2026 release (November 5, 2026): revenue from continuing operations $567.8 million, +0.2% reported and +3.0% pro forma adjusted constant currency; GAAP diluted EPS $1.30, adjusted diluted EPS $2.63 (vs $1.89).
- Pro forma adjusted constant currency growth by segment: Vascular +4.6%, Interventional +0.2%, Surgical +5.1%; nine months +4.2% in total.
- 2026 guidance: pro forma adjusted constant currency revenue growth maintained at 3.5%-4.5%; GAAP revenue growth cut to 13.2%-14.2% on FX (revenue $2,256-2,276 million); adjusted EPS raised to $7.50-$7.75, GAAP EPS $2.84-$3.09.
- Adjusted operating margin assumption for 2026 about 20.0% (19.0% previously), including $16.5 million of IEEPA tariff refunds for 2026.
- CEO Jason Weidman: priorities are delivering the transformation (divestitures and VI integration), organizational effectiveness and a higher growth profile; he expects "a meaningful step-up in adjusted earnings per share in 2027".
- Innovation: Freesolve resorbable magnesium scaffold got FDA Breakthrough Device Designation for PCI; EZPLAZ freeze-dried plasma seen as a U.S. market opportunity of at least $200 million.
- Capital: $350 million repurchased since July 1, 2026; $400 million left of the $1 billion authorization; OEM sale brought $1.25 billion after-tax proceeds.

### [Teleflex Q3 2026 Earnings Call Transcript](https://www.tradingkey.com/news/transcripts/262283725-)

Executive talk · Jason Weidman, President and Chief Executive Officer · 2026-11-05

- Q3 2026 earnings call (November 5, 2026) with CEO Jason Weidman and CFO John Deren: pro forma adjusted constant currency revenue growth 3%, adjusted operating margin 25%, adjusted EPS $2.63 (+39.2%).
- Weidman's three priorities: strengthen the foundation (close the Acute Care and IU divestiture, finish the Interventional integration), accelerate organizational effectiveness (global business units, simpler operating model), elevate growth (innovation and capital allocation).
- Teleflex now runs three global business units, Vascular, Interventional and Surgical; Weidman said the old geographic structure created "a complex matrix".
- VI integration: about 90% of VI customers moved to Teleflex ordering, 87% of the indirect business under Teleflex distributors, open sales territories down 63% from peak; Jason Fontana leads Interventional.
- R&D raised from about 5%-6% of revenue to close to 8%; Freesolve has FDA breakthrough device designation and BIOMAG trial data are due late 2027; EZPLAZ U.S. opportunity at least $200 million, U.S. government and military first.
- Capital: $1 billion buyback and $800 million debt reduction; net leverage about 1.4x; operating margin expected to approximate 23% in the first year after the Acute Care and IU close.
- Tariffs a little over $30 million in 2026 and expected to be similar in 2027; no 2027 guidance until the next call.

### [Teleflex (TFX) Q2 2026 Earnings Call Transcript](https://www.fool.com/earnings/call-transcripts/2026/08/13/teleflex-tfx-q2-2026-earnings-call-transcript/)

Executive talk · Jason Weidman, President and Chief Executive Officer · 2026-08-06

- Q2 2026 earnings call (August 6, 2026), Jason Weidman's first as CEO (two months in), with CFO John Deren: revenue $570.3 million, +28.9% reported and +4.7% pro forma adjusted constant currency; adjusted EPS $1.76.
- Vascular $246.3 million (+8%) and Surgical $112.1 million (+9.2%) were strong; Interventional $211.9 million (-1%) suffered from a slower VI integration.
- Weidman named three transient integration issues, order-to-cash, distributor and sales force transitions, saying "this is absolutely not a product issue"; full integration pushed through the second half of 2026.
- 2026 guidance: constant currency growth cut to 3.5%-4.5% (from 4.5%-5.5%), entirely on Interventional; adjusted EPS raised to $6.90-$7.20; adjusted operating margin about 19%; steady-state margin about 23%.
- OEM divestiture closed ($1.5 billion, $1.25 billion after tax); $250 million ASR started August 7; $700 million term loan repaid; plan of $1 billion buybacks and $800 million debt reduction.
- Innovation: EZPLAZ freeze-dried plasma FDA approval in late July (U.S. government and military first); Freesolve BIOMAG-II enrollment completed, BIOMAG-III U.S. pivotal trial started; R&D at 7.9% of sales in H1 2026.

## Questions about Teleflex

### What does Teleflex do?

Teleflex designs and manufactures single-use medical devices for critical care and surgical procedures, organised into Vascular, Interventional and Surgical units.

### What is Teleflex's revenue?

FY2025 net revenues from continuing operations were $1,992.7 million; 2026 guidance is $2,256-2,276 million.

### How many employees does Teleflex have?

Approximately 15,500 at December 31, 2025, before the divestitures.

### Who leads Teleflex?

Jason Weidman has been President and CEO since June 8, 2026; John R. Deren is CFO and Andrew A. Krakauer is Chairman.

### What is Teleflex's strategy?

Teleflex is divesting Acute Care, Interventional Urology and OEM to focus on three global units, raising R&D, simplifying its operating model and returning capital through buybacks and debt reduction.

_Written by Tamtam from the company's own published documents listed above, read in full. Figures are as those documents state them, for the periods they name. (2026-11-17)_
